Saturday, 21 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 21 December 2024
News

Blockbuster faces surprise generics

Posted 3 October 2024 AM

A long-fought-over drug suddenly faced generic competition at the start of October, knocking around $35 million from its earnings - and putting a significant dent in a $140 million-a-year-plus franchise.

Bayer's anti-coagulant Xarelto will take a 25 per cent first new brand price reduction with the PBS listing of two generic versions, Teva's Rivaroxaban-Teva and Alphapharm's iXarola. Alphapharm is now Viatris.

To see the whole article, please login

Popular

Who got booted to the May meet?
Best company Christmas gift is...
First out the door in '25?
He's back: Ex-GM wins CEO role
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home